These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 30762305

  • 1. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
    Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T.
    CPT Pharmacometrics Syst Pharmacol; 2019 May; 8(5):296-307. PubMed ID: 30762305
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K, Huth F, Jin Y, Schiller H, Aslanis V, Heimbach T, He H.
    Drug Metab Pers Ther; 2019 May 30; 34(2):. PubMed ID: 31145690
    [Abstract] [Full Text] [Related]

  • 6. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y, Loi CM, Hoffman J, Wang D.
    J Clin Pharmacol; 2017 Feb 30; 57(2):173-184. PubMed ID: 27402157
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C, Fan B, Ke A, Le K, Yang H.
    Cancer Chemother Pharmacol; 2020 Nov 30; 86(5):619-632. PubMed ID: 32978634
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
    Samant TS, Huth F, Umehara K, Schiller H, Dhuria SV, Elmeliegy M, Miller M, Chakraborty A, Heimbach T, He H, Ji Y.
    Clin Pharmacol Ther; 2020 Sep 30; 108(3):575-585. PubMed ID: 32557601
    [Abstract] [Full Text] [Related]

  • 11. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
    Turner PK, Hall SD, Chapman SC, Rehmel JL, Royalty JE, Guo Y, Kulanthaivel P.
    Drug Metab Dispos; 2020 Sep 30; 48(9):796-803. PubMed ID: 32581049
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.
    Salem F, Johnson TN, Abduljalil K, Tucker GT, Rostami-Hodjegan A.
    Clin Pharmacokinet; 2014 Jul 30; 53(7):625-36. PubMed ID: 24671884
    [Abstract] [Full Text] [Related]

  • 15. PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
    Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T.
    CPT Pharmacometrics Syst Pharmacol; 2018 Oct 30; 7(10):647-659. PubMed ID: 30091221
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
    Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X.
    Br J Clin Pharmacol; 2009 Dec 30; 68(6):928-35. PubMed ID: 20002088
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
    Baneyx G, Parrott N, Meille C, Iliadis A, Lavé T.
    Eur J Pharm Sci; 2014 Jun 02; 56():1-15. PubMed ID: 24530864
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
    Li Y, Liu L, Wang X, Zhang C, Reyes J, Hoffmann M, Palmisano M, Zhou S.
    J Clin Pharmacol; 2018 Oct 02; 58(10):1295-1304. PubMed ID: 29762875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.